Status:
COMPLETED
Chemoradiotherapy HNSCC, Randomized Study, Docetaxel,Cisplatin, 5FU,Erbitux.
Lead Sponsor:
Groupe Oncologie Radiotherapie Tete et Cou
Conditions:
Squamous Cell Head and Neck Carcinoma
Eligibility:
All Genders
18-70 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to demonstrate that induction chemotherapy followed by radiation therapy plus Cetuximab will give better results than the validated treatment (chemoradiotherapy), for trea...
Detailed Description
Concurrent chemoradiotherapy (radiotherapy+ carboplatin + 5FU) is a validated treatment for patients with locoregional advanced head and neck cancers. This study evaluates the outcome of induction ch...
Eligibility Criteria
Inclusion
- head and neck locally advanced,non metastatic carcinoma
- not suitable for surgery
Exclusion
- non squamous cell head and neck cancer
- previous malignancy
- previous treatment
Key Trial Info
Start Date :
May 18 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 6 2018
Estimated Enrollment :
370 Patients enrolled
Trial Details
Trial ID
NCT01233843
Start Date
May 18 2009
End Date
November 6 2018
Last Update
January 18 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
GIRARD CALAIS Marie-Helene
Tours, France, 37044